… Differences in the risk of recurrent venous thromboembolism and major bleeding events …
safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism …

… We conducted a randomized, placebo-controlled, double-blind clinical trial assessing the
efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in ambulatory …

… apixaban is thought to offer similar protection against recurrent venous thromboembolism
(… The study described here aimed to compare the effectiveness and safety of use of apixaban …

… and safety of apixaban during the initial 6-month treatment of venous thromboembolism in
… The favorable safety profile that we found for apixaban is in agreement with the results of …

… efficacy and safety of apixaban with the efficacy and safety of … with deep-vein thrombosis,
pulmonary embolism, or both. … the initial deep-vein thrombosis or pulmonary embolism, and all …

… Apixaban (Eliquis ® ) is an oral, direct factor Xa inhibitor that is available for use in the … of
venous thromboembolism (VTE). Like other direct oral anticoagulants (DOACs), apixaban has …

… embolism) and AMPLIFY (Oral apixaban for the treatment of acute venous thromboembolism)]
that established the safety and efficacy of rivaroxaban and apixaban were heterogeneous. …

… -EXT) study, we compared the efficacy and safety of these two doses of apixaban with those
of placebo in patients with venous thromboembolism who had completed 6 to 12 months of …

… Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is approved for the acute treatment
of deep-vein thrombosis (DVT) and pulmonary embolism (… safety and efficacy of apixaban, …

… , apixaban was non-inferior to warfarin plus subcutaneous enoxaparin bridge therapy in the
treatment of acute venous thromboembolism … comparative effectiveness and safety in routine …